Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...

PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Aspirin has been shown to effectively reduce recurrence rates and improve disease-free survival,” said Anna Martling, MD, PhD.

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on ...